In chronic HF, empagliflozin reduced a composite of CV death or HF hospitalization across kidney risk categories

Ali Ziaolhagh; Donald A Molony

doi:10.7326/J23-0065

In chronic HF, empagliflozin reduced a composite of CV death or HF hospitalization across kidney risk categories

Ann Intern Med. 2023 Sep;176(9):JC101. doi: 10.7326/J23-0065. Epub 2023 Sep 5.

Authors

Ali Ziaolhagh¹, Donald A Molony¹

Affiliation

¹ UT-McGovern Medical School, Houston, Texas, USA (A.Z., D.A.M.).

PMID: 37665991
DOI: 10.7326/J23-0065

Abstract

Butler J, Packer M, Siddiqi TJ, et al. Efficacy of empagliflozin in patients with heart failure across kidney risk categories. J Am Coll Cardiol. 2023;81:1902-1914. 37164523.

Publication types

Comment

MeSH terms

Benzhydryl Compounds* / therapeutic use
Glucosides* / therapeutic use
Hospitalization
Humans
Kidney

Substances

empagliflozin
Benzhydryl Compounds
Glucosides